Local Immunological Effect of Neoadjuvant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Cancer

被引:0
|
作者
Murakami, T. [1 ]
Mori, R. [1 ]
Matsuyama, R. [1 ]
Homma, Y. [1 ]
Nakazawa, M. [2 ]
Tanaka, Y. [1 ]
Miyake, K. [1 ]
Sawada, Y. [1 ]
Oota, Y. [1 ]
Hiroshima, Y. [1 ]
Kumamoto, T. [1 ]
Ueda, M. [1 ]
Takeda, K. [1 ]
Ichikawa, Y. [1 ]
Tanaka, K. [1 ]
Endo, I. [1 ]
机构
[1] Yokohama City Univ, Grad Sch Med, Dept Surg Gastroenterol, Yokohama, Kanagawa 232, Japan
[2] Yokohama City Univ, Grad Sch Med, Dept Expt Anim Med, Yokohama, Kanagawa 232, Japan
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
引用
收藏
页码:1394 / 1394
页数:1
相关论文
共 50 条
  • [1] Neoadjuvant Chemoradiotherapy for Resectable and Borderline Resectable Pancreatic Cancer
    Attaallah, Wafi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 3346 - +
  • [2] Neoadjuvant Chemoradiotherapy for Resectable and Borderline Resectable Pancreatic Cancer
    Hayakawa, S.
    Karasawa, K.
    Fujisawa, T.
    Ito, K.
    Shibata, Y.
    Shimizuguchi, T.
    Nihei, K.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E236 - E236
  • [3] Immunological Impact of Neoadjuvant Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Yuki Homma
    Koichi Taniguchi
    Takashi Murakami
    Kazuya Nakagawa
    Masatoshi Nakazawa
    Ryusei Matsuyama
    Ryutaro Mori
    Kazuhisa Takeda
    Michio Ueda
    Yasushi Ichikawa
    Kuniya Tanaka
    Itaru Endo
    [J]. Annals of Surgical Oncology, 2014, 21 : 670 - 676
  • [4] Immunological Impact of Neoadjuvant Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Homma, Yuki
    Taniguchi, Koichi
    Murakami, Takashi
    Nakagawa, Kazuya
    Nakazawa, Masatoshi
    Matsuyama, Ryusei
    Mori, Ryutaro
    Takeda, Kazuhisa
    Ueda, Michio
    Ichikawa, Yasushi
    Tanaka, Kuniya
    Endo, Itaru
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (02) : 670 - 676
  • [5] Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy
    di Sebastiano, Pierluigi
    Grottola, Tommaso
    di Mola, F. Francesco
    [J]. UPDATES IN SURGERY, 2016, 68 (03) : 235 - 239
  • [6] Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy
    Pierluigi di Sebastiano
    Tommaso Grottola
    F. Francesco di Mola
    [J]. Updates in Surgery, 2016, 68 : 235 - 239
  • [7] Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
    Thanikachalam, Kannan
    Damarla, Vijay
    Seixas, Trevor
    Dobrosotskaya, Irina
    Wollner, Ira
    Kwon, David
    Winters, Kenneth
    Raoufi, Mohammad
    Li, Jia
    Siddiqui, Farzan
    Khan, Gazala
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (06): : 435 - 441
  • [8] Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
    Versteijne, Eva
    de Hingh, Ignace H. J. T.
    Homs, Marjolein Y. V.
    Intven, Martijn P. W.
    Klaase, Joost M.
    van Santvoort, Hjalmar C.
    de Vos-Geelen, Judith
    Wilmink, Johanna W.
    van Tienhoven, Geertjan
    [J]. FRONTIERS IN ONCOLOGY, 2022, 11
  • [9] Effect of neoadjuvant chemoradiotherapy on prognosis in resectable and borderline resectable pancreatic cancer with venous involvement.
    Nagai, Minako
    Sho, Masayuki
    Akahori, Takahiro
    Nakagawa, Kenji
    Nakamura, Kota
    Takagi, Tadataka
    Tanaka, Toshihiro
    Nishiofuku, Hideyuki
    Kichikawa, Kimihiko
    Ikeda, Naoya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [10] Neoadjuvant chemoradiotherapy with S-1 in patients with borderline resectable pancreatic cancer
    Hattori, Masashi
    Fujii, Tsutomu
    Suenaga, Masaya
    Yamada, Suguru
    Kanda, Mitsuro
    Iwata, Naoki
    Kobayashi, Daisuke
    Tanaka, Chie
    Nakayama, Goro
    Sugimoto, Hiroyuki
    Koike, Masahiko
    Nomoto, Shuji
    Fujiwara, Michitaka
    Kodera, Yasuhiro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)